Stemirna Therapeutics Co., Ltd.

“Currently More Than 35 mRNA Cancer Vaccines Are In Clinical Trials” mRNA cancer vaccines represent a groundbreaking immunotherapy approach designed to target cancer by leveraging the body's own immune system to recognize and attack cancer cells. Unlike traditional vaccines, which often use weakened or inactivated pathogens to stimulate an immune response, mRNA vaccines work by delivering genetic instructions to cells to produce specific antigens found on cancer cells. These antigens then trigger an immune response, including the activation of T cells, which can recognize and destroy cancer cells. The development of mRNA cancer vaccines has been fueled by advancements in mRNA technology, including improved delivery systems and optimization of mRNA sequences for enhanced protein expression and immunogenicity. This has enabled researchers to target a wide range of cancer antigens, including tumor-specific antigens and shared antigens expressed across various cancer types. Download mRNA Cancer Vaccine Clinical Trials Market Opportunity Research One of the key advantages of mRNA cancer vaccines is their ability to induce a robust and specific immune response against cancer cells while minimizing off-target effects on healthy tissues. Additionally, mRNA vaccines offer flexibility in manufacturing, allowing for rapid production and adaptation to emerging cancer targets or mutations. Apart from that, mRNA vaccines can be tailored to target a wide range of cancer antigens, including tumor-specific antigens and shared antigens across multiple cancer types. This customization allows for personalized treatment approaches that take into account the unique characteristics of each patient's tumor, potentially improving treatment efficacy. Owing to numerous advantages that comes along with the utilization of mRNA cancer vaccines results in leveraging this potential in clinical research with the intention of providing treatment to many patients suffering from cancer and other diseases. Clinical trials evaluating mRNA cancer vaccines have shown promising results across multiple cancer types, demonstrating their potential as a new therapeutic approach in oncology. These vaccines have been shown to stimulate immune responses, induce tumor regression, and improve survival outcomes in some patients. Multitudinous clinical trials ongoing for mRNA cancer vaccines are being conducted by various pharma or biotech companies, research hospitals and universities aross the world which includes Fudan University, Stemirna Therapeutics, The First Affiliated Hospital of Zhengzhou University, Peking University Cancer Hospital & Institute, Merck, Moderna, Second Affiliated Hospital of Guangzhou Medical University, BioNTech, Hangzhou Neoantigen Therapeutic, Sir Run Run Shaw Hospital, CureVac, Translate Bio, and other. The presences of giant pharmaceutical companies in the domain further aid to expand the domain of mRNA cancer vaccines worldwide. As of March 2024, no mRNA vaccines have been approved for cancer treatment; yet there is anticipation that an innovative and cutting edge mRNA cancer vaccine will be launched in commercial market as evident from rising research along with involvement of giant pharma companies. For instance, clinical trials for mRNA-4157/V940, an experimental personalized mRNA cancer vaccine, along with Keytruda (pembrolizumab) are ongoing which are being partnered by Moderna and Merck. The clinical trial data demonstrated the customized mRNA vaccine, when administered in conjunction with Merck's Keytruda, reduced the risk of melanoma death or recurrence by 44% when compared to Keytruda used alone. All these examples illustrates that the realm of mRNA cancer vaccines is expanding. The market potential for mRNA cancer vaccines is significant, driven by growing demand for innovative cancer therapies and advancements in immunotherapy. Key factors contributing to the market growth include increasing investment in mRNA technology, favorable regulatory environment, and expanding clinical pipeline of mRNA cancer vaccines. Moreover, the potential for personalized vaccines tailored to individual patients' tumor antigens presents additional opportunities for market expansion. Despite challenges, the future outlook for mRNA cancer vaccines is promising. Continued advancements in mRNA technology, expanding clinical pipelines, and increasing investment in research and development are expected to drive market growth. Additionally, the potential for personalized vaccines tailored to individual patient profiles presents a lucrative opportunity for market expansion. In conclusion, mRNA cancer vaccines represent a paradigm shift in cancer treatment, offering a potent and personalized immunotherapy approach. With robust market drivers, technological advancements, and growing investment, the market for mRNA cancer vaccines is poised for substantial growth in the coming years. However, addressing manufacturing challenges, managing adverse events, and optimizing personalized approaches will be critical to realizing the full potential of mRNA cancer vaccines in the fight against cancer.

Closure of pre-A financing round led by LAMPAM Capital Dual internal discovery platforms of small molecule and AAV-based gene therapy targeting neurological and psychiatric disorders SHANGHAI, Sept. 29, 2022 /PRNewswire/ -- NeuShen Therapeutics, Inc., a biotechnology company focusing on developing innovative treatments for central nervous system (CNS) disorders with dual platforms of AAV-based gene therapy and small molecule discovery, announced today the closure of ~$20 million Series pre-A financing led by LAPAM, a China based venture capital. NeuShen was founded by a group of industrial executives who have extensive global experiences in central nervous system (CNS) drug development. The new capital will be used to expand the team and catalyze in-house CNS drug discovery in both the US and China. Continue Reading Dr. Joan Shen, Founder and CEO of Neushen Therapeutics "The successful completion of this fundraising is a testimony to our team's ability to accomplish CNS drug development and jump starts our discovery engine to build a pipeline with AAV-based gene therapy and small molecule programs," said Joan Shen, M.D., Ph.D., chief executive officer and founder of NeuShen. "CNS disease is an area with huge unmet needs. Our company has had a very clear goal from Day 1, which is to develop novel therapies to relieve the burdens of patients with CNS disorders. In the past few months, we have developed an achievable R&D strategy and built-up a substantial core team with experienced CNS drug hunters. Significant progress has been made in building the internal small molecule pipeline and new AAV gene therapy programs. In addition, multiple collaborations and partnerships have been discussed and established." CNS disorders are increasingly recognized as major causes of death and disability worldwide while the diagnosis and treatments have largely lagged. Urgent measures are needed to tackle the growing challenges. "Bringing breakthroughs and learnings from other disease targets such as ophthalmology, oncology and hematology, we believe AAV-based gene therapy represents a new opportunity in the treatment of CNS disorders. My colleagues and I at Horae Gene Therapy Center are looking forward to working with Neushen to explore these treatment opportunities. The experiences of NeuShen team in neurosciences will be critical to make this happen," noted Dr. Guangping Gao, Professor, Director, Horae Gene Therapy Center, UMass Chan Medical School. The collaborations between NeuShen and UMass are currently in discussion, which will include multiple projects in CNS gene therapy. "We are very excited to partner with NeuShen from the beginning. Lapam Capital has a strong commitment to healthcare, and we believe the CNS therapeutic area will attract more investment, considering the huge unmet needs and scientific advancements in the field. We highly value Dr. Joan Shen and her management team for their expertise. Lampam Capital is confident with NeuShen's ability to be a top player in developing innovative therapies for CNS diseases," said Mr. Zhihua Yu, Managing Director of Lapam Capital. "Dr. Shen has assembled a pre-eminent group of scientists, clinicians and drug developers to build a global biotech developing novel medicines for unmet needs in CNS therapeutic areas. TTM Capital are excited to support Neushen to build its multi-modality pipelines to help patients worldwide," said Ms. Lilly Zhang, founding and managing partner at TTM Capital. About NeuShen Therapeutics NeuShen Therapeutics is a biotechnology company focusing on innovative drug research and development to address CNS disorders, applying dual research platforms, including AAV-based gene therapy and small molecule discovery. With operations both in Shanghai, China and Boston, MA, NeuShen has a world-class team and is honored to be advised by an outstanding Board of Directors and Scientific Advisory Board. About Lapam Capital Headquartered in Beijing, Lapam Capital is a leading healthcare venture capital firm in China. Lapam is currently managing five RMB funds and one USD fund, with more than 10 billion RMB under management. Lapam Capital focuses on investments in early to middle stage fast-growing companies that have innovative pharmaceuticals and medical devices. It has invested in about 60 biopharmaceutical companies and 10 medical device companies to date, including Betta Pharma, RemeGen Co. Ltd., Clover Biopharmaceuticals, Yahong Meditech, Stemirna Therapeutics, Binhui Biotech, ImmuneOnco Biopharmaceuticals, Biostar Pharmaceuticals, Aibo Medical Robot Co. Ltd. and many other companies with great potential. Lapam Capital has a professional investment team with more than 20 years' international and domestic biopharmaceutical industry R&D and management experience and can provide comprehensive value-added supports for the invested companies. About TTM Capital TTM Capital is an investment firm that specializes in China and worldwide healthcare industry. We focus on early and growth stage companies including pharmaceutical, biotech and medical technology sub-sectors. TTM Capital's team consists of experienced global vision investment professionals with extensive industry experience, who work together to achieve superior and consistent returns for the firm's investors. We are committed to accumulating industry experience over time, with the aim to develop an ecosystem of expertise to create transformative healthcare businesses. SOURCE NeuShen Therapeutics

Funding to accelerate the discovery and development of drugs for high value and traditionally undruggable targets SAN JOSE, Calif., July 27, 2022 /PRNewswire/ -- BridGene Biosciences, Inc., a biotechnology company leveraging a proprietary chemoproteomic platform to discover and develop small-molecule drugs for high-value, traditionally undruggable targets, today announced the completion of a $38.5 million Series B financing by Lapam Capital, Junson Capital and Dyee Capital. Proceeds from the offering will be used to further develop BridGene's chemoproteomic platform IMTAC™, which enables the screening of small molecules against the whole proteome or against a prioritized target in live cells to discover drug candidates for high value and traditionally undruggable targets that drive diseases, including cancers. The unique advantage of IMTAC™ is that it can efficiently identify hits for two major types of traditionally undruggable targets. By using covalent small molecules, BridGene can identify hits for targets with shallow binding pockets. BridGene can also identify hits via live cell screening for targets with temporary binding pockets that only form in live cells such as protein: protein interactions. This brings unprecedented opportunities for the development of small-molecule drugs for traditionally undruggable targets. The proceeds will also be used to develop BridGene's leading pipeline project, a covalent TEAD inhibitor, as well as a few other undisclosed first-in-class oncology pipeline projects, which were initiated based on discoveries using the IMTAC™ platform. "This financing, along with our collaboration with Takeda Pharmaceutical announced last year, significantly strengthens our resources to discover breakthrough medicines for patients," said Ping Cao, Ph.D., CEO and co-founder of BridGene. "Our pioneering work has expanded the scope of chemoproteomics technology from screening just covalent small molecules to also screening non-covalent small molecules, and from targeting just cysteine to targeting multiple amino acids. Our technology uniquely enables us to discover small-molecule drugs for traditionally undruggable targets with unparalleled speed and efficiency. It also enables us to build a pipeline with first-in-class drugs targeting well-known high-value and traditionally undruggable targets. Our long-term goal is to find small-molecule drugs for the most important targets in the proteome." "BridGene's chemoproteomics platform IMTAC™ is impressive and unique. It breaks the limitations of traditional chemoproteomics technology and greatly expands its scope. BridGene has established an outstanding scientific team, which has extensive experience in chemoproteomic technology and drug development. We believe that BridGene has the potential to grow to a leading company in the field of drugging traditionally undruggable targets," said Mr. Zhihua Yu, Chairman of Lapam Capital. About Lapam Capital Headquartered in Beijing, Lapam Capital is a leading healthcare venture capital firm in China. Lapam is currently managing five RMB funds and one USD fund, with more than 10 billion RMB under management. Lapam Capital focuses on investments in early to middle stage fast-growing companies that have innovative pharmaceuticals and medical devices. It has invested in about 60 biopharmaceutical companies and 10 medical device companies to date, including Betta Pharma, RemeGen Co. Ltd., Clover Biopharmaceuticals, Yahong Meditech, Stemirna Therapeutics, Binhui Biotech, ImmuneOnco Biopharmaceuticals, Biostar Pharmaceuticals, Aibo Medical Robot Co. Ltd. and many other companies with great potential. Lapam Capital has a professional investment team with more than 20 years' international and domestic biopharmaceutical industry R&D and management experience and can provide comprehensive value-added supports for the invested companies. About Junson Capital Junson Capital is a global multi-asset investment management company with venture capital and private equity, public market investments, real estate investments, and alternative investments. With its long dedication to technology and healthcare, Junson Capital manages more than 30 portfolio companies and aims at backing disruptive technology and science leaders. As a global organization, Junson Capital has investment professionals located in Hong Kong, New York, Palo Alto and Singapore. About Dyee Capital Dyee Capital focuses on investments in the fields of healthcare and information technology. The management team has many years of investment, investment banking, and industry experience, as well as extensive market resources and professional post-investment service experience. Dyee Capital has invested in many innovative pharmaceutical companies, including Zelgen Biopharmaceuticals, Allist Pharmaceuticals, InventisBio, Ionova Life Science, Ark Biosciences, Leads Biolabs, Yingli Pharma, and Zhimeng Biopharma. About BridGene Biosciences BridGene is a biotechnology company focused on discovering and developing innovative small molecules that drug traditionally undruggable targets, providing new paths to treat diseases. By using its proprietary chemoproteomics platform, IMTAC™, BridGene can screen small molecules against proteins in live cells to discover drug candidates for high value and traditionally undruggable targets. For this purpose, BridGene takes advantage of its proprietary, diverse library of tagged, drug-like small molecules. The ultimate goal is to enable breakthrough small molecule drug discovery with expanded mechanisms to treat diseases with targets previously inaccessible to small molecules. The uniqueness of BridGene's technology allows it to perform IMTAC™ screening for both covalent and non-covalent molecules, target different amino acids and discover new targets for disease treatments by deconvoluting phenotypic screening hits. The company is advancing a diversified pipeline of first-in-class drugs for targets in multiple disease areas. For more information, visit . Contact Tiberend Strategic Advisors, Inc. Investors Jonathan Nugent +1-205-566-3026 [email protected] Media Bill Borden +1-732-910-1620 [email protected] Dave Schemelia +1-609-468-9325 [email protected] SOURCE BridGene Biosciences